ABSTRACT
【Objective】 To investigate the effect of Qingkailing injection on platelet function preserved in vitro. 【Methods】 A total of 15 bags of plateletpheresis (≥250 mL/bag), adding Qingkailing injection(1.25 mL/bag) at the final concentration of 1%, were stored at 22 ℃ with gentle agitation as the experimental group, and samples were collected on day 1, 3, 5, 8, 10 and 14 to detect the thromboelastogram (TEG), CD62p expression rate and mitochondrial membrane potential (JC-1). The control group was set up synchronously, with the same volume and storage conditions as the experimental groups, and samples were taken on day 1, 3 and 5 after preservation to undertake the same test items as the experimental groups. The differences of detection indexes between the two groups were compared. 【Results】 1) In the experimental group, there was no significant change in K and α during day 1 to 14(P>0.05). The R value (min) increased from 6.12±1.58 to 11.02±2.26, and the CI value changed from 0.27±1.24 to -10.47±3.51 (P0.05), but decreased to 53.18±2.71 on day 8 and 22.88±3.45 on day 14 (P0.05), but JC-1 (%) was 86.75±3.88 vs 70.36±19.8 on day 5 (P<0.05). In the experimental group, JC-1(%) was 81.04±9.50 vs 71.38±8.77 vs 82.77±7.17 on day 8, 10 and 14, respectively. 【Conclusion】 The activation and aggregation as well as anti-apoptosis function of plateletpheresis, adding Qingkailing injection at the final concentration of 1%, are similar to those of routine preservation.
ABSTRACT
Objective To investigate the clinical value of C-reactive protein (CRP) combined with prothrombin time (PT) and partially activated thromboplastin time (APTY) in the diagnosis of neonatal late-onset sepsis.Methods From January 2013 to January 2018,100 neonates with sepsis admitted to our department of neonatology in Lishui Maternal and Child Health-Care Center were collected.According to the results of blood culture,neonates with positive blood culture were classified as sepsis group A (53 cases),and neonates with negative blood culture were classified as sepsis group B (47 cases).Another 50 normal newborns born at the same period were included in the control group.The CRP,PT and APTT values of the three groups were detected and compared.The receiver-operating characteristic curves (ROC) were plotted to obtain the area under ROC curve (AUC) and the sensitivity,specificity,positive predictive value and negative predictive value.Another ROC curve was plotted to obtain the area under ROC curve (AUC) and the sensitivity,specificity,positive predictive value,and negative predictive value for a new variable,CPR + PT + APTT,which was established using a binomial logistic regression method.Results The results of CPR,PT and APTT in the control group,sepsis group A and sepsis group B all increased in turn (F=10.616,6.155,5.243,P =0.000,0.000,0.000).CPR + PT + APTT had the largest AUC (0.94),the highest sensitivity (93.42％),the highest specificity (91.66％),the highest positive predictive value (92.60％),and the highest negative predictive value (78.55％) in the four indicators.Conclusion When blood culture fails to diagnose late-onset neonatal sepsis,combined detection of CPR + PT + APTT can provide some clues for its early diagnosis,which is worthy of clinical attention.
ABSTRACT
Objective To evaluate the short -term efficacy and long-term efficacy of thoracic radiotherapy combined with gefitinib in the treatment of elderly patients with advanced non -small cell lung cancer . Methods From October 2012 to October 2015 , 120 elderly patients with advanced non -small cell lung cancer confirmed by histopathology as adenocarcinoma in the Third People's Hospital of Linyi were selected .Using envelope method,the patients were randomly divided into observation group and control group ,with 60 cases in each group .In the observation group ,IMRT was performed on pulmonary lesions ,and 125 mg of gefitinib was also given orally .The control group received IMRT .All patients were followed up , and the short -term efficacy , quality of life and the incidence of side effects in the two groups were observed .Results In terms of short-term efficacy,the RR of the observation group and the control group was 83.3％ vs.50.0％(χ2 =9.16,P=0.001),the disease control rate (DCR) of the observation group and the control group was 100.0％ vs.83.3％(χ2 =6.48,P=0.003),the PD of the observation group and the control group was 16.7％ vs.0.0％(χ2 =8.16, P =0.001 ).At 3 months after radiotherapy,the RR,DCR and PD of the observation group and the control group were 86.7％ vs.50.0％(χ2 =9.86,P=0.001),100.0％ vs.76.7％(χ2 =7.42,P=0.003),23.3％ vs.0.0％(χ2 =11.24,P=0.000).One year after radiotherapy,the RR of the observation group and the control group was 73.3％ vs.33.3％(χ2 =11.16, P=0.000),the DCR of the observation group and the control group was 54.0％vs.60.0％(χ2 =8.48,P=0.001), the PD of the observation group and the control group was 10.0％ vs.40.0％(χ2 =9.48,P=0.001).There was statistically significant difference between the two groups (P<0.05).As to the long-term efficacy,the progression-free survival (PFS) of the observation group and the control group was (17.64 ±1.86) months vs.(13.26 ± 1.82) months (t=7.28,P =0.000);overall survival (OS) was (26.16 ±2.14) months vs.(17.82 ± 2.02) months (t=10.62,P=0.000).The difference was statistically significant (P<0.05).The quality of life of the patients in the observation group was significantly better than that in the control group at 3 months,1 year and 2 years after radiotherapy (P <0.05).There was no statistically significant difference between the two groups in leukopenia,thrombocytopenia, anemia, esophagitis, radiation pneumonitis, gastrointestinal reaction, rash and other adverse reactions(all P >0.05).Conclusion Radiotherapy combined with gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer has better short -term and long-term efficacy ,it can significantly improve the patients ' efficacy and DCR , prolong the patients ' disease PFS time and OS time , improve patients ' quality of life.And did not increase adverse reactions ,it is worthy of clinical application .